Eugene Schneider
Chief Tech/Sci/R&D Officer bij IONIS PHARMACEUTICALS, INC.
Vermogen: 2 M $ op 31-03-2024
Actieve functies van Eugene Schneider
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| IONIS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - | - |
Excellus Health Plan, Inc.
 Excellus Health Plan, Inc. Managed Health CareHealth Services Excellus Health Plan, Inc. provides health care and long term care insurance plans for individuals and families, sole proprietors, small businesses, and midsize and large businesses in New York. The company is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | - | - |
Loopbaan van Eugene Schneider
Eerdere bekende functies van Eugene Schneider
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Biovail Technologies Ltd. | Chief Tech/Sci/R&D Officer | - | - |
| SYNAGEVA BIOPHARMA CORP | Chief Tech/Sci/R&D Officer | - | - |
Opleiding van Eugene Schneider
| University of Medicine & Dentistry of New Jersey | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Chief Tech/Sci/R&D Officer | 4 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
| Health Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Excellus Health Plan, Inc.
Excellus Health Plan, Inc. Managed Health CareHealth Services Excellus Health Plan, Inc. provides health care and long term care insurance plans for individuals and families, sole proprietors, small businesses, and midsize and large businesses in New York. The company is headquartered in New York, NY. | Health Services |
| Biovail Technologies Ltd. | |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
- Beurs
- Insiders
- Eugene Schneider
- Ervaring
